Bilkent University · Molecular Biology and Genetics
We study how individual PI3K isoforms, oncogenic mutations and PTEN loss rewire lipid signalling — and how tumours escape the drugs designed to stop them.
Research
Three connected questions about how PI3K signalling is wired, how it breaks in cancer, and how tumours survive the drugs aimed at it.
Which PI3K isoform does what, and how activating mutations turn that division of labour into a driver of cancer.
Why tumours stop responding to PI3K inhibitors, and which combinations put the pressure back on.
How PTEN loss rewires lipid metabolism, and whether that rewiring can be targeted or read as a biomarker.
The pathway
Follow the signal from the receptor to the nucleus — then switch on a hotspot mutation, delete PTEN, or add an inhibitor and watch what changes.
Interactive figure
Scroll the figure sideways to follow the cascade.
Publications
Turkish Journal of Biochemistry · 2024
News
Our work on biotinylated diaryl isoxazole derivatives with enhanced JAK1 inhibitory, antiproliferative and apoptotic activity is out in ACS Omega.
Three projects from the group have been accepted for funding under the TÜSEB 2026 A and B Group calls.
Recruitment runs on a periodic basis; applications usually open in June and again in November.
